Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In addition, each group was further subdivided into a metabolic health group and a metabolic syndrome group according to ...

Korea University Guro Hospital has opened the Alzheimer's Prevention Center (Center Director Kang Sung-hoon).The Alzheimer's ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

Deep sleep could be key to forestalling slow declines in brain health that may one day lead to Alzheimer's disease, the most ...

Every anti-amyloid antibody is different, hence the donanemab AUR address two unique aspects of this drug: in its Phase 3 trial, scientists used baseline tau PET scans to determine eligibility, and ...

Q3 2024 Earnings Call Transcript November 6, 2024 Lantheus Holdings, Inc. beats earnings expectations. Reported EPS is $1.79, ...

Riyadh: The signing of a Memorandum of Understanding (MoU) between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) would pave the way to transform ...

Weill Cornell Medicine researchers have received a five-year, $6.2 million grant from the National Institute on Aging, part of the National Institutes ...